|Bid||12.45 x 800|
|Ask||23.00 x 800|
|Day's Range||21.77 - 22.46|
|52 Week Range||21.31 - 47.22|
|Beta (3Y Monthly)||3.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Our latest Health Care Digest is taking names and targeting the latest in biotech and health care news.
The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent […]
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you canRead More...
Cancer remains the company's main focus, but it also is pushing to transform treatment of multiple sclerosis.
As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.
We can judge whether Atara Biotherapeutics Inc (NASDAQ:ATRA) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into their best […]
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.29. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.15. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...